HC Wainwright Estimates Cytokinetics Q3 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Investment analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Cytokinetics in a note issued to investors on Wednesday, February 25th. HC Wainwright analyst J. Pantginis forecasts that the biopharmaceutical company will earn ($2.03) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $136.00 target price on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ FY2026 earnings at ($7.12) EPS, FY2027 earnings at ($5.12) EPS and FY2028 earnings at ($1.67) EPS.

Several other brokerages have also issued reports on CYTK. Bank of America restated a “neutral” rating on shares of Cytokinetics in a research note on Wednesday. Royal Bank Of Canada lifted their target price on shares of Cytokinetics from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Friday, February 20th. JPMorgan Chase & Co. lifted their price objective on shares of Cytokinetics from $70.00 to $74.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Leerink Partners boosted their price objective on Cytokinetics from $83.00 to $84.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Citizens Jmp lifted their target price on Cytokinetics from $88.00 to $96.00 and gave the company a “market outperform” rating in a report on Wednesday. Seventeen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Cytokinetics presently has an average rating of “Moderate Buy” and a consensus target price of $88.83.

Cytokinetics Stock Performance

Shares of NASDAQ:CYTK opened at $62.63 on Friday. Cytokinetics has a fifty-two week low of $29.31 and a fifty-two week high of $70.98. The company’s 50-day moving average is $64.21 and its 200 day moving average is $58.38. The company has a market capitalization of $7.66 billion, a P/E ratio of -9.59 and a beta of 0.54.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The business had revenue of $17.76 million during the quarter, compared to analyst estimates of $8.02 million. During the same quarter in the previous year, the business posted ($1.26) EPS. The company’s quarterly revenue was up 4.9% on a year-over-year basis.

Insider Activity

In other news, Director Wendell Wierenga sold 20,000 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $66.14, for a total value of $1,322,800.00. Following the sale, the director directly owned 32,444 shares of the company’s stock, valued at approximately $2,145,846.16. This represents a 38.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Andrew Callos sold 15,000 shares of the company’s stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $61.93, for a total transaction of $928,950.00. Following the completion of the transaction, the executive vice president owned 50,440 shares in the company, valued at approximately $3,123,749.20. The trade was a 22.92% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 151,385 shares of company stock worth $9,817,158. Corporate insiders own 2.70% of the company’s stock.

Institutional Trading of Cytokinetics

Several institutional investors have recently added to or reduced their stakes in CYTK. Bank of Montreal Can boosted its position in shares of Cytokinetics by 1.2% during the fourth quarter. Bank of Montreal Can now owns 13,292 shares of the biopharmaceutical company’s stock valued at $845,000 after buying an additional 160 shares during the last quarter. Kennedy Capital Management LLC lifted its stake in Cytokinetics by 1.2% during the 4th quarter. Kennedy Capital Management LLC now owns 13,183 shares of the biopharmaceutical company’s stock valued at $838,000 after acquiring an additional 162 shares during the period. UMB Bank n.a. boosted its holdings in shares of Cytokinetics by 10.6% during the 3rd quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 169 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Cytokinetics by 46.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 171 shares during the last quarter. Finally, Vident Advisory LLC grew its stake in shares of Cytokinetics by 1.4% in the fourth quarter. Vident Advisory LLC now owns 16,455 shares of the biopharmaceutical company’s stock worth $1,046,000 after acquiring an additional 234 shares during the period.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright reiterates a “Buy” and models near‑term quarterly EPS (Q1: -$1.57, Q2: -$1.61, Q4: -$1.89) while assigning a $136 price target — a substantial upside that supports longer‑term investor interest. HC Wainwright estimates
• Positive Sentiment: Analysts have been raising price targets: Citizens JMP to $96 (market outperform), Leerink Partners to $84 (outperform), and Needham to $85 (buy) — these upgrades add upward pressure on sentiment. Benzinga price target coverage
• Positive Sentiment: Zacks notes Cytokinetics is advancing Myqorzo launch plans after FDA activity and highlights a ~$1.22B cash position, which supports funding for commercialization and 2026 catalysts. Myqorzo launch & cash runway
• Positive Sentiment: Retail/permissioned coverage and bullish opinion pieces (e.g., Villanovan profile) are promoting a buy case based on pipeline and commercialization upside. Why Cytokinetics Is a Buy
• Neutral Sentiment: Q4 earnings call and transcript coverage are available for deeper read‑throughs of management commentary on margins, SG&A, and launch timing (useful for assessing execution risk). Earnings call transcript (InsiderMonkey) Earnings transcript (Seeking Alpha) Earnings transcript (Yahoo)
• Neutral Sentiment: Reported short‑interest data appears anomalous/zero in the latest release, so there’s no clear short‑squeeze signal from those figures. (No actionable short‑pressure evidence.)
• Negative Sentiment: Q4 results showed a slightly wider-than-expected loss (EPS -$1.50 vs. estimate -$1.48) and higher expenses year‑over‑year — a near‑term negative that likely pressured the stock despite revenue outperformance. Q4 results coverage

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.